lecanemab approved Leqembi
Selected indexed studies
- Lecanemab: Appropriate Use Recommendations. (J Prev Alzheimers Dis, 2023) [PMID:37357276]
- Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. (Alzheimers Res Ther, 2024) [PMID:38730496]
- Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease. (Adv Clin Exp Med, 2023) [PMID:37676096]
_Worker-drafted node — pending editorial review._
Connections
lecanemab approved Leqembi is a side effect of
Sources
- Alzheimer's Disease: Treatment Challenges for the Future. (2025) pubmed
- The Black Book of Psychotropic Dosing and Monitoring. (2024) pubmed
- Donanemab: Appropriate use recommendations. (2025) pubmed
- Lecanemab: Appropriate Use Recommendations. (2023) pubmed
- Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. (2024) pubmed
- Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. (2023) pubmed
- Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. (2022) pubmed
- A 2025 update on treatment strategies for the Alzheimer's disease spectrum. (2025) pubmed
- Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease. (2023) pubmed
- Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) pubmed